Cover Image
市場調查報告書

亞太地區到2021年的乾癬治療藥市場:新生技藥品的登場和治療池的擴大促進成長

Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth

出版商 GBI Research 商品編碼 331415
出版日期 內容資訊 英文 94 Pages
訂單完成後即時交付
價格
Back to Top
亞太地區到2021年的乾癬治療藥市場:新生技藥品的登場和治療池的擴大促進成長 Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth
出版日期: 2015年05月01日 內容資訊: 英文 94 Pages
簡介

亞太地區的乾癬治療藥市場,從2014年的6億9,000萬美元,至2021年擴大到12億美元規模,預計以年複合成長率8.4%成長。

本報告提供亞太地區乾癬治療藥市場相關調查分析、市場概要、上市產品、開發中產品、市場預測、交易和策略性整合等相關的系統性資訊。

第1章 目錄

第2章 簡介

  • 症狀
  • 病因、共生病症和危險因素
  • 病理生理學
  • 診斷
  • 流行病學
  • 治療和管理

第3章 上市產品

  • 概要
  • Methotrexate產品
  • Sandimmune/Neoral (cyclosporine/modified cyclosporin)
  • Humira (adalimumab)
  • Enbrel (etanercept)
  • Remicade (infliximab)
  • Stelara (ustekinumab)
  • 有效性和安全性比較

第4章 乾癬市場:開發中產品

  • 概要
  • 整體開發平台
  • 開發平台分析:各分子類型
  • 開發平台分析:各分子標的
  • 臨床試驗
  • 開發平台上的有前途藥物的候補

第5章 市場預測

  • 各地區市場
    • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
  • 推動因素與阻礙
    • 推動因素
    • 障礙

第6章 交易與策略性整合

  • 主要的共同開發交易
  • 主要的許可證交易

第7章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GBIHC360MR

Executive Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth", which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research's team of industry experts.

In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $435m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $773m. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results. However, during the forecast period, biologics are likely gain a significant market share due to healthcare plans in APAC and awareness regarding the effectiveness of biologics. Among the recently launched biologics, Cosentyx (secukinumab) from Novartis has shown better efficacy than Enbrel (etanercept), and is a novel molecule that targets Interluekin-17 (IL-7). Biocon India has launched Alzumab (itolizumab), which is a first-in-class novel molecule that targets CD6 protein. It is anticipated to be the leading biologic in India by the end of forecast period. Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab) are expected to lose their patent during the forecast period, but will be compensated for by biosimilar versions.

Scope

The report analyzes treatment use patterns, market characterization, the pipeline, and key licensing and co-development deals for psoriasis in the APAC markets of China, India, Japan, and Australia.The report includes -

  • A brief introduction to psoriasis, including pathophysiology, etiology, diagnosis, and treatment algorithms
  • In-depth analysis of currently marketed drugs, including analysis of safety, efficacy, treatment patterns, and strengths/weaknesses, along with a heat map comparing them in terms of safety and efficacy
  • A comprehensive review of the pipeline for psoriasis, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period; the pipeline is further analyzed on the basis of phase distribution, molecule type, program type, mechanism of action, and molecular target
  • Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration, and program failure rate for each molecule type
  • Multi-scenario forecast data for the market to 2021, taking into account how it might be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets
  • Discussion of the drivers of and barriers to market growth
  • In-depth analysis of all licensing and co-development deals that have occurred in the psoriasis market since 2006

Reasons to buy

  • The report will enhance your decision-making capability by allowing you to -
  • Understand the psoriasis pipeline and the factors that indicate that it is becoming more innovative
  • Analyze detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be
  • Follow the trends in psoriasis clinical trial size and duration in relation to industry averages
  • Assess the potential risk of future developmental programs for psoriasis therapeutics by mechanism of action using recorded clinical trial failure rates
  • Analyze the potential growth patterns expected for the psoriasis market over the forecast period
  • Identify the countries that are expected to contribute the most to this growth and devise a more effectively tailored country strategy through an understanding of key drivers and barriers
  • Accelerate and strengthen your market position by identifying key companies for strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Symptoms
    • 2.1.1. Skin Manifestations
    • 2.1.2. Psychological Impact
  • 2.2. Etiology, Co-morbidities and Risk Factors
    • 2.2.1. Genetics
    • 2.2.2. Psoriatic Arthritis
    • 2.2.3. Mental Health Disorders
    • 2.2.4. Metabolic Syndrome, Smoking, Diet and Alcohol Consumption
    • 2.2.5. Infections
    • 2.2.6. Koebner Phenomenon
    • 2.2.7. Other Immune-Mediated Diseases
  • 2.3. Pathophysiology
  • 2.4. Diagnosis
  • 2.5. Epidemiology
  • 2.6. Treatment and Management
    • 2.6.1. Pharmacological Therapies
    • 2.6.2. Non-pharmacological Therapies
    • 2.6.3. Combination and Rotational Therapies
    • 2.6.4. Quality of Life Assessments
    • 2.6.5. Summary

3. Marketed Products

  • 3.1. Overview
  • 3.2. Methotrexate-Based Products
  • 3.3. Sandimmune/Neoral (cyclosporine/modified cyclosporin)-Novartis
  • 3.4. Humira (adalimumab)-AbbVie
  • 3.5. Enbrel (etanercept)-Amgen
  • 3.6. Remicade (infliximab)-Janssen Biotech
  • 3.7. Stelara (ustekinumab)-Janssen Biotech
  • 3.8. Comparative Efficacy and Safety

4. Psoriasis Market to 2021-Pipeline Products

  • 4.1. Overview
  • 4.2. Overall Pipeline
  • 4.3. Pipeline Analysis by Molecule Type
  • 4.4. Pipeline Analysis by Molecular Target
  • 4.5. Clinical Trials
    • 4.5.1. Overall Failure Rate
    • 4.5.2. Failure Rate by Molecule Type
    • 4.5.3. Failure Rate by Molecular Target
    • 4.5.4. Patient Enrollment and Clinical Trial Size
    • 4.5.5. Duration
    • 4.5.6. Summary of Psoriasis Clinical Trials
  • 4.6. Promising Drug Candidates in the Pipeline
    • 4.6.1. LY2439821(ixekizumab)-Eli Lilly
    • 4.6.2. Xeljanz (tofacitinib)-Pfizer
    • 4.6.3. Brodalumab-Amgen

5. Market Forecast to 2021

  • 5.1. Geographical Markets
    • 5.1.1. Asia-Pacific Market Overview
    • 5.1.2. China
    • 5.1.3. India
    • 5.1.4. Japan
    • 5.1.5. Australia
  • 5.2. Drivers and Barriers
    • 5.2.1. Drivers
    • 5.2.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Major Co-development Deals
    • 6.1.1. AbbVie Enters into Co-development Agreement with Biotest for Tregalizumab
    • 6.1.2. Lycera Enters into Research Agreement with Merck
    • 6.1.3. LEO Pharma Enters into Research Agreement with 4SC Discovery for Inflammatory Skin Diseases
    • 6.1.4. Amgen Enters into Co-Development Agreement with AstraZeneca for Five Human Monoclonal Antibodies Including Brodalumab
  • 6.2. Major Licensing Deals
    • 6.2.1. Leo Pharma Enters into Licensing Agreement with Virobay for Psoriasis Drug
    • 6.2.2. Foamix Enters into Licensing Agreement with Dr. Reddy's Laboratories
    • 6.2.3. Cipher Pharmaceuticals Enters into Licensing Agreement with IBSA Institut Biochimique for Betesil Patch
    • 6.2.4. Phenex Pharmaceuticals Enters into Licensing Agreement with Janssen Biotech for Retinoid-Acid Receptor-Related Orphan Receptor Gamma. Program

7. Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-Filed
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
    • 7.1.7. Pre-registration
  • 7.2. Market Forecasts to 2021
    • 7.2.1. Asia-Pacific
    • 7.2.2. China
    • 7.2.3. India
    • 7.2.4. Japan
    • 7.2.5. Australia
  • 7.3. Market Definitions
  • 7.4. Abbreviations
  • 7.5. References
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Psoriasis Market, Global, Types of Psoriasis, 2015
  • Table 2: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Discovery, 2014
  • Table 3: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014
  • Table 4: Psoriasis Market, Therapeutics, Global, All Pipeline Products, IND/CTA-Filed, 2014
  • Table 5: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Phase I, 2014
  • Table 6: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Phase II, 2014
  • Table 7: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Phase III, 2014
  • Table 8: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Pre-registration, 2014
  • Table 9: Psoriasis Market, Asia-Pacific, Forecast Data, 2014-2021
  • Table 10: Psoriasis Market, China, Forecast Data, 2014-2021
  • Table 11: Psoriasis Market, India, Forecast Data, 2014-2021
  • Table 12: Psoriasis Market, Japan, Forecast Data, 2014-2021
  • Table 13: Psoriasis Market, Australia, Forecast Data, 2014-2021

List of Figures

  • Figure 1: Psoriasis Market, Global, Composite Treatment Algorithm, 2015
  • Figure 2: Psoriasis Market, Global, Humira (adalimumab), Annual Sales ($bn), 2007-2014
  • Figure 3: Psoriasis Market, Global, Enbrel (etanercept), Annual Sales ($bn), 2007-2014
  • Figure 4: Psoriasis Market, Global, Remicade (infliximab), Annual Sales ($bn), 2007-2014
  • Figure 5: Psoriasis Market, Global, Stelara (ustekinumab), Annual Sales ($bn), 2010-2014
  • Figure 6: Psoriasis Market, Global, Comparative Safety and Efficacy of Marketed Products Heatmap (1/2), 2015
  • Figure 7: Psoriasis Market, Global, Comparative Safety and Efficacy of Marketed Products Heatmap (2/2), 2015
  • Figure 8: Psoriasis Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2015
  • Figure 9: Psoriasis Market, Global, Pipeline by Molecule Type and Stage of Development, 2015
  • Figure 10: Psoriasis Market, Global, Pipeline by Molecular Target (1/2), 2015
  • Figure 11: Psoriasis Market, Global, Pipeline by Molecular Target (2/2), 2015
  • Figure 12: Psoriasis Market, Global, Pipeline by Molecular Target, Molecule Type and Stage of Development, 2015
  • Figure 13: Psoriasis Market, Global, Clinical Trial Failure Rate (%), 2015
  • Figure 14: Psoriasis Market, Global, Clinical Trial Failure Rate by Molecule Type (%), 2015
  • Figure 15: Psoriasis Market, Global, Clinical Trial Failure Rate by Molecular Target (%), 2015
  • Figure 16: Psoriasis Market, Global, Clinical Trial Size, 2015
  • Figure 17: Psoriasis Market, Global, Clinical Trial Duration (months), 2015
  • Figure 18: Psoriasis Systemic Therapy Market, Asia-Pacific, Treatment Use Patterns and Market Size ($m), 2014-2021
  • Figure 19: Psoriasis Systemic Therapy Market, China, Treatment Use Patterns, Annual Cost of Therapy ($) and Market Size ($m), 2014-2021
  • Figure 20: Psoriasis Systemic Therapy Market, India, Treatment Use Patterns, Annual Cost of Therapy ($), and Market Size ($m), 2014-2021
  • Figure 21: Psoriasis Systemic Therapy Market, Japan, Treatment Use Patterns, Annual Cost of Therapy ($), Market Size ($m), 2014-2021
  • Figure 22: Psoriasis Systemic Therapy Market, Australia, Treatment Use Patterns, Annual Cost of Therapy ($), Market Size ($m), 2014-2021
  • Figure 23: Psoriasis Market, Global, Co-development Deals by Geography, Deals by Value, 2006-2014
  • Figure 24: Psoriasis Market, Global, Co-development Deals by Year, Deals by Phase and Molecule Type, 2006-2014
  • Figure 25: Psoriasis Market, Global, Co-development Deals by Molecule Type and Deal Value, Deals by Molecular Target and Deal Value, 2006-2014
  • Figure 26: Psoriasis Market, Global, Co-development Deals by Geography, 2006-2014
  • Figure 27: Psoriasis Market, Global, Licensing Deals by Geography and Value, 2006-2014
  • Figure 28: Psoriasis Market, Global, Licensing Deals by Year, Licensing Deals by Phase and Molecule Type, 2006-2014
  • Figure 29: Psoriasis Market, Global, Licensing Deals by Year and by Phase, 2006-2014
  • Figure 30: Psoriasis Market, Global, Licensing Deals by Geography, 2006-2014
  • Figure 31: GBI Research Market Forecasting Model (Example)
Back to Top